{"id":2386,"date":"2025-01-10T16:42:40","date_gmt":"2025-01-10T13:42:40","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2386"},"modified":"2025-11-03T20:30:56","modified_gmt":"2025-11-03T17:30:56","slug":"plans-for-dyne-101-in-dm1-and-dyne-251-in-dmd-are-announced-by-dyne-therapeutics","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/es\/plans-for-dyne-101-in-dm1-and-dyne-251-in-dmd-are-announced-by-dyne-therapeutics\/","title":{"rendered":"Dyne Therapeutics anuncia planes para DYNE-101 en DM1 y DYNE-251 en DMD"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Dyne Therapeutics anunci\u00f3 datos cl\u00ednicos positivos para sus terapias DYNE-101 y DYNE-251 durante un evento para inversores el 10 de enero de 2025. DYNE-101 para la distrofia miot\u00f3nica tipo 1 (DM1) demostr\u00f3 una correcci\u00f3n de empalme significativa y mejoras funcionales, lo que llev\u00f3 a Dyne a planificar una cohorte de expansi\u00f3n de registro global del ensayo ACHIEVE con una dosis de registro de 6,8 mg\/kg Q8W y una posible presentaci\u00f3n de aprobaci\u00f3n acelerada en EE. UU. en el primer semestre de 2026.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Mientras tanto, DYNE-251, un f\u00e1rmaco contra la distrofia muscular de Duchenne (DMD), tambi\u00e9n est\u00e1 buscando la aprobaci\u00f3n acelerada en Estados Unidos bas\u00e1ndose en la distrofina como criterio de valoraci\u00f3n sustituto, y se espera que los datos est\u00e9n disponibles a fines de 2025 para respaldar una presentaci\u00f3n a principios de 2026. Ambos programas son prometedores en la transformaci\u00f3n de los paradigmas de tratamiento para estas enfermedades gen\u00e9ticas.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Leer m\u00e1s<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/es\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Ensayos cl\u00ednicos para la distrofia muscular de Duchenne (Lista de todas las investigaciones)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Dyne Therapeutics announced positive clinical data for its therapies DYNE-101 and DYNE-251 during an investor event on January 10, 2025. DYNE-101 for myotonic dystrophy type 1 (DM1) demonstrated significant splicing correction and functional improvements, leading Dyne to plan a global Registrational Expansion Cohort of the ACHIEVE trial with a registrational dose of 6.8 mg\/kg Q8W [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2388,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[118,66,143,144,145],"class_list":["post-2386","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-duchenne","tag-duchenne-muscular-dystrophy","tag-dyne","tag-dyne-101","tag-dyne-251"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/2386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/comments?post=2386"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/2386\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media\/2388"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media?parent=2386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/categories?post=2386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/tags?post=2386"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}